IDEAYA Biosciences Secures IND Clearance for IDE275 (GSK959) to Initiate Phase 1 Trial in MSI-High Solid Tumors

MGI Partners with OncoDNA to Enhance Precision Oncology with Compatible Genomic Solutions

Tempus Partners with JW Pharmaceutical to Leverage Real-World Data and Biological Modeling for Enhanced R&D

Devyser Secures NMPA Approval for Devyser Compact, Expanding Genetic Testing Market in China

Qure.ai Partners with Roche’s Startup Creasphere to Enhance Healthcare Innovation in APAC

Six NHS Trusts to Deploy deepc’s AI Radiology Platform in Partnership with AI4VBC

Precision Medicine Program Marks Major Advancement in Kidney Transplant Care for Hereditary Kidney Disease Patients

Helio Genomics and Halub Medical Announce Partnership to Launch HelioLiver Dx in GCC and Middle East

Merck's KEYTRUDA® (pembrolizumab) Secures 30th European Commission Approval with Two New Indications for Gynecologic Cancers

Dyno Therapeutics Expands Collaboration with Roche to Develop Next-Generation Gene Therapies for Neurological Diseases

Philips and Medtronic Partner to Advance Stroke Care and Awareness

Qatar Precision Health Institute Unveils Genomic Data and Announces New Research Initiatives

Caris Life Sciences Partners with ECOG-ACRIN to Advance Precision Medicine in Breast Cancer Research

Celemics and Strand Life Sciences Strengthen Partnership for Enhanced NGS Analysis

Thermo Fisher Partners with Telangana Government to Launch Bioprocess Design Centre in Hyderabad

Home
/
update
/
details

QIAGEN Digital Insights Launches Pharmacogenomic Insights (PGXI) to Advance Precision Medicine

NextEdge Admin

23 Oct 2024

2 min 8 sec

QIAGEN Digital Insights (QDI), a leader in bioinformatics software and biomedical knowledge, has introduced Pharmacogenomic Insights (PGXI), a new knowledgebase designed to help researchers understand how genetic variations impact drug responses. PGXI streamlines the analysis of pharmacogenomic markers, accelerating drug development and personalized treatment.

Built on a proven platform responsible for delivering over 1.6 million pharmacogenomic annotations to 250+ clinical labs, PGXI consolidates data from key sources, including the FDA, CPIC, DPWG, PharmVar, and PubMed. This unified repository provides up-to-date, evidence-based insights, enabling users to query gene-drug associations and genotype-linked conditions swiftly.

The tool automates complex genetic analysis, identifying haplotypes and diplotypes—key to understanding individual drug responses—while producing standardized, easy-to-interpret reports. This ensures faster, more confident decision-making, integrating seamlessly into existing workflows without the need for technical expertise.

“Researchers often face challenges accessing scattered pharmacogenomic data,” said Dominic John, Head of QDI. “PGXI addresses this by offering a single, continuously updated resource, allowing users to quickly generate actionable insights.”

By cutting the time required for pharmacogenomic analysis from hours to minutes, PGXI transforms precision medicine, empowering researchers to reduce side effects, improve drug efficacy, and personalize therapies more efficiently. With 25+ years of experience, QDI supports over 90,000 users and 4 million profiled patient cases worldwide, driving breakthroughs in healthcare through scalable, intuitive bioinformatics solutions.